for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ORIC Pharmaceuticals Inc

ORIC.OQ

Latest Trade

21.33USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

18.76

 - 

40.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Oric Pharmaceuticals Posts Qtrly Net Loss Per Share Of $0.84

March 23 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND OPERATIONAL UPDATE.ORIC PHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.84.

Oric Pharmaceuticals Provides Corporate Update And Highlights Key 2021 Milestones

Jan 11 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS KEY 2021 MILESTONES.ORIC PHARMACEUTICALS INC - THREE IND/CTA FILINGS FOR ORIC-533, -944, AND -114 EXPECTED IN 2021.ORIC - LEAD PROGRAM ORIC-101 CONTINUES ENROLLMENT INVESTIGATING TWO THERAPEUTIC MECHANISMS OF ACTION, ON TRACK FOR TWO INITIAL DATA READOUTS IN 2021.ORIC PHARMA- CO EXPECTS ITS CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLAN INTO SECOND HALF OF 2023.

Oric Pharmaceuticals Inc Files For Offering Of Up To 4.0 Million Shares Of Common Stock - SEC Filing

Nov 10 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 4.0 MILLION SHARES OF COMMON STOCK - SEC FILING.

Oric Pharmaceuticals Reports Proposed Public Offering Of Common Stock

Nov 10 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 4.00 MILLION COMMON SHARES.

Oric Pharmaceuticals Inc Says Qtrly Loss Per Share $0.84

Nov 5 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::QTRLY LOSS PER SHARE $0.84.ORIC PHARMACEUTICALS - EXPECTS CURRENT CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLAN INTO H2 OF 2022.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $186.6 MILLION AS OF SEPTEMBER 30, 2020.Q3 EARNINGS PER SHARE VIEW $-0.39 -- REFINITIV IBES DATA.

ORIC Pharmaceuticals Says It Expanded Precision Oncology Pipeline

Oct 19 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS EXPANDS PRECISION ONCOLOGY PIPELINE WITH EXCLUSIVE LICENSE TO BRAIN PENETRANT EGFR/HER2 EXON 20 INHIBITOR PROGRAM.ORIC PHARMACEUTICALS INC - INITIATION OF GLOBAL PHASE 1/2 TUMOR-AGNOSTIC TRIAL IN GENETICALLY DEFINED CANCERS EXPECTED IN SECOND HALF OF 2021.ORIC PHARMACEUTICALS INC - ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH VORONOI, INC..ORIC - SECURED EXCLUSIVE RIGHTS WORLDWIDE EXCLUDING CHINA, HONG KONG, MACAU AND TAIWAN FOR DEVELOPMENT AND COMMERCIALIZATION OF ORIC-114.ORIC PHARMACEUTICALS - IF ORIC PURSUES SECOND LICENSED PRODUCT, ORIC WOULD PAY VORONOI UP TO ADDITIONAL $272 MILLION IN SUCCESS-BASED MILESTONES.ORIC PHARMACEUTICALS INC - WILL ALSO PAY TIERED MID-SINGLE-DIGIT TO LOW DOUBLE-DIGIT ROYALTIES BASED ON ANNUAL NET SALES IN ORIC TERRITORY.

Oric Pharmaceuticals Announces Presentation Of Preclinical Data On Glucocorticoid Receptor Antagonist Overcoming Resistance To An Androgen Receptor Degrader At The 32Nd EortcNciAacr Symposium 20

Oct 9 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA ON GLUCOCORTICOID RECEPTOR ANTAGONIST OVERCOMING RESISTANCE TO AN ANDROGEN RECEPTOR DEGRADER AT THE 32ND EORTC-NCI-AACR SYMPOSIUM 2020.ORIC PHARMACEUTICALS INC - EXPECTS TO REPORT INTERIM DATA FROM ONE OF TRIALS IN FIRST HALF OF 2021 AND FROM OTHER TRIAL IN SECOND HALF OF 2021.

Oric Pharmaceuticals Reports Qtrly Loss Per Share $0.51

Aug 5 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL AND OPERATIONAL UPDATE.ORIC PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.51.ORIC PHARMACEUTICALS - EXPECTS CURRENT CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND CURRENT OPERATING PLAN INTO Q4 OF 2022.

Oric Pharmaceuticals Reports Q1 Loss Per Share Of $4.46

May 20 (Reuters) - Oric Pharmaceuticals Inc <ORIC.O>::ORIC PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATIONAL RESULTS.ORIC PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $4.46.ORIC PHARMACEUTICALS INC SAYS CASH AND CASH EQUIVALENTS OF $204.2 MILLION AS OF APRIL 30, EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2023.

Orbimed Advisors Llc Reports 9.2% Stake In Oric Pharmaceuticals Inc As Of April 28

May 1 (Reuters) - Orbimed Advisors Llc::ORBIMED ADVISORS LLC REPORTS 9.2% STAKE IN ORIC PHARMACEUTICALS INC AS OF APRIL 28 - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up